TITLE:
A candidate identification questionnaire for postmenopausal osteoporosis patients switched from daily or weekly bisphosphonate to once-monthly ibandronate: An open, prospective, multicenter study—BONCURE study
AUTHORS:
Yesim Gokce Kutsal, Nurten Eskiyurt, Jale Irdesel, Vesile Sepici, Hatice Ugurlu, Yesim Kirazli, Fusun Ardic, Mirko Korsic, Tonko Vlak, Mane Grlickov, Snezana Markovic Temelkova, Miroslav Lazarov, Nada Pilipovic, Vera Popovic, Aleksandar Dimic, Branka Kovacev, Dorina Ruci, Argjend Tafaj, Elma Kucukalic-Selimovic, Dijana Avdic, Hajrija Seleskovic, Snjezana Pejicic, Bulent Butun, Gulseren Akyuz, Lale Cerrahoglu, Omer Faruk Sendur, Peyman Yalcin, Sema Oncel, Merih Saridogan, Tunay Sarpel, Mehmet Tosun, Kazim Senel, Savas Gursoy, Ferhan Canturk, Huseyin Demir, Blazenka Miskic, Dalibor Krpan, Franjo Skreb, Simeon Grazio, Zeljka Crncevic-Orlic, Fatih Ozdener, Hakan Oncel
KEYWORDS:
Bisphosphonate; Compliance; Ibandronate; Postmenopausal Osteoporosis
JOURNAL NAME:
Health,
Vol.5 No.7B,
July
16,
2013
ABSTRACT:
A candidate identification questionnaire
(CIQ) was tested to determine its predictive value for patient-reported satisfaction in patients switched from once-weekly
or once-daily treatment with a bisphosphonate to once-monthly dosing. This was a
prospective, open-label, multicenter international study in patients with postmenopausal
osteoporosis who had been receiving once-daily or once-weekly alendronate or risendronate
for at least 3 months. Patients completed
a CIQ, then commenced 150 mg monthly ibandronate for 6 months. Patients completed the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-QTM)
at baseline for 6 months. Scores were converted to composite satisfaction scores
(CSS, scale 0-100). Totally 677 patients completed a CIQ, 645 were enrolled in
the treatment phase and comprised the intent-to-treat (ITT) population, and 630
completed the study. In the ITT population, 68.1% patients answered “yes” to one
or more CIQ questions. OPSAT-Q scores increased for the convenience, quality of
life and overall satisfaction domains (p scores for the side effects
domains were significant (p preferred
the once-monthly dosing schedule and 563 patients (90.7%) found it more
convenient. The most common adverse events were dyspepsia (1.9%), nausea (1.1%),
and upper abdominal pain (0.9%). Patients are likely to prefer treatment with monthly
ibandronate to a weekly or monthly bisphosphonate irrespective of their stated preference
before switching treatment.